TY - JOUR
T1 - Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins
AU - Lo, Li Wei
AU - Chen, Yao Chang
AU - Chen, Yi Jen
AU - Wongcharoen, Wanwarang
AU - Lin, Cheng I.
AU - Chen, Shih Ann
N1 - Funding Information:
The present work was supported by the Topnotch Stroke Research Center Grant, Ministry of Education and grants NSC 94-2314-B-075-093, NSC 94-2314-B-010-056, NSC-94-2314-B-010-053, NSC 95-2314-B-016-015, NSC 95-2314-B-038-026, VGH 94-204, VGH-94-005, VGH-94-206, VGH-94-009, V95A-008 and SKH-TMU-94-01 from Shih Kong Wu Ho-Su Memorial Hospital.
PY - 2007/10/1
Y1 - 2007/10/1
N2 - The autonomic nervous system and calcium regulation play important roles in the pathophysiology of atrial fibrillation. Calmodulin regulates the calcium homeostasis and may mediate the proarrhythmic effects of autonomic nervous agents. The purpose of this study was to compare the effects of β- and α-adrenoceptor agonists on the pulmonary vein electrical activity and evaluate whether calmodulin kinase II inhibitors may change the effects of the adrenoceptor agonists on the pulmonary vein arrhythmogenesis. Conventional microelectrodes were used to record the action potentials in isolated rabbit pulmonary vein tissue specimens before and after the administration of isoproterenol, phenylephrine and KN-93 (a calmodulin kinase II inhibitor). In the tissue preparation, isoproterenol (0, 0.1, 3 μM) increased the beating rates (1.5 ± 0.2, 1.6 ± 0.2, 2.3 ± 0.3 Hz, n = 10, P < 0.001) with the genesis of early afterdepolarizations (EADs, 0%, 40%, 50%, P < 0.05) and increased the amplitude of the delayed afterdepolarizations (DADs, 0.6 ± 0.3, 1.7 ± 0.4, 3.9 ± 1.0 mV, P < 0.05). Phenylephrine (0, 1, 10 μM) also increased the beating rates (1.4 ± 0.2, 1.6 ± 0.2, 1.9 ± 0.2 Hz, n = 12, P < 0.001), incidence of EADs (0%, 8%, 50%, P < 0.05) and amplitude of the DADs (0.4 ± 0.2, 1.2 ± 0.4, 2.6 ± 0.8 mV, P < 0.05). KN-93 did not change the pulmonary vein beating rates or action potential duration. However, in the presence of KN-93 (1 μM), isoproterenol (3 μM) and phenylephrine (10 μM) did not induce any EADs or DADs in the pulmonary veins. In conclusion, calmodulin kinase II inhibition may prevent adrenergic induced pulmonary vein arrhythmogenesis.
AB - The autonomic nervous system and calcium regulation play important roles in the pathophysiology of atrial fibrillation. Calmodulin regulates the calcium homeostasis and may mediate the proarrhythmic effects of autonomic nervous agents. The purpose of this study was to compare the effects of β- and α-adrenoceptor agonists on the pulmonary vein electrical activity and evaluate whether calmodulin kinase II inhibitors may change the effects of the adrenoceptor agonists on the pulmonary vein arrhythmogenesis. Conventional microelectrodes were used to record the action potentials in isolated rabbit pulmonary vein tissue specimens before and after the administration of isoproterenol, phenylephrine and KN-93 (a calmodulin kinase II inhibitor). In the tissue preparation, isoproterenol (0, 0.1, 3 μM) increased the beating rates (1.5 ± 0.2, 1.6 ± 0.2, 2.3 ± 0.3 Hz, n = 10, P < 0.001) with the genesis of early afterdepolarizations (EADs, 0%, 40%, 50%, P < 0.05) and increased the amplitude of the delayed afterdepolarizations (DADs, 0.6 ± 0.3, 1.7 ± 0.4, 3.9 ± 1.0 mV, P < 0.05). Phenylephrine (0, 1, 10 μM) also increased the beating rates (1.4 ± 0.2, 1.6 ± 0.2, 1.9 ± 0.2 Hz, n = 12, P < 0.001), incidence of EADs (0%, 8%, 50%, P < 0.05) and amplitude of the DADs (0.4 ± 0.2, 1.2 ± 0.4, 2.6 ± 0.8 mV, P < 0.05). KN-93 did not change the pulmonary vein beating rates or action potential duration. However, in the presence of KN-93 (1 μM), isoproterenol (3 μM) and phenylephrine (10 μM) did not induce any EADs or DADs in the pulmonary veins. In conclusion, calmodulin kinase II inhibition may prevent adrenergic induced pulmonary vein arrhythmogenesis.
KW - Adrenoceptor agonist
KW - Atrial fibrillation
KW - Calmodulin kinase II inhibitor
KW - Pulmonary vein
KW - Triggered activity
UR - http://www.scopus.com/inward/record.url?scp=34548595644&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2007.05.066
DO - 10.1016/j.ejphar.2007.05.066
M3 - Article
C2 - 17612522
AN - SCOPUS:34548595644
SN - 0014-2999
VL - 571
SP - 197
EP - 208
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -